A simple, precise, fast and gradient, high performance liquid chromatographic (HPLC) method was developed and validated for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in solid dosage forms. The quantitative determination of analyte(s) was performed on a PUROSPHERE STAR RP 18e analytical column (250×4.6 mm) with 0.2 %v/v TEA buffer (pH: 3.0): ACN as mobile phase, at a flow rate of 1.0 mL min -1 . Detection was made by extracting PDA spectra at 215 nm respectively. During method validation, parameters such as precision, linearity, stability, Robustness, Ruggedness and specificity were evaluated, which remained within acceptable limits. The method has been successfully applied to assess the assay of solid dosage formulations.
Introduction:
Hypertension or high blood pressure is a chronic medical condition in which the blood pressure in the arteries is elevated. It is classified as either primary (essential) or secondary. About 90-95 % of cases are termed "primary hypertension", which refers to high blood pressure for which no medical cause can be found the remaining 5-10 % of cases (Secondary hypertension) are caused by another conditions that affect the kidneys, arteries, heart, or endocrine system. Blood pressure is classified based on two types of measurements, the systolic and diastolic blood pressures expressed as a ratio such as '120 over 80' (120/80) mmHg. Systolic blood pressure is the blood pressure in vessels during a heart beat. Diastolic blood pressure is the pressure between heartbeats. Aliskiren (Figure1a), a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of Aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients. Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases. Aliskiren administered both orally or intravenously. Aliskiren is also available as combination therapy with Hydrochlorothiazide. Ramipril (Figure1b) is an angiotensinconverting enzyme (ACE) inhibitor, used to treat hypertension and congestive heart failure. ACE inhibitors lower the production of angiotensin II, therefore relaxing arterial muscles while at the same time enlarging the arteries, allowing the heart to pump blood more easily, and increasing blood flow due to more blood being pumped into and through larger passageways. Ramipril is a prodrug and is converted to the active metabolite ramiprilat by liver esterase enzymes. Valsartan (Figure1c) is in a class of drugs called angiogenesis II receptor antagonists. This medicine works by preventing constriction (narrowing) of blood vessels (veins and arteries). Valsartan is used to treat high blood pressure (hypertension), congestive heart failure and to reduce cardiovascular death in patients. Valsartan is available as tablets for oral administration, containing 40 mg, 80 mg, 160 mg or 320 mg of valsartan. Valsartan may cause hypotension if it is taken with other heart medication. is a first line diuretic drug of the thiazide class that acts by inhibiting the kidneys' ability to retain water. This reduces the volume of the blood, decreasing blood return to the heart. Hydrochlorothiazide is used to treat excessive fluid accumulation and swelling (edema) of the body caused by heart failure, cirrhosis, chronic kidney failure, corticosteroid medications, and nephrotic syndrome. The usual adult dose for hypertension is 12.5 to 50 mg once daily. The usual adult dose for treating edema is 25-100 mg once daily or in divided doses. Blood sugar levels can be elevated by hydrochlorothiazide, necessitating adjustment in the doses of medications that are used for treating diabetes. The safety and efficacy of drug therapy can be ensured using a validated analytical method to assess the quality of pharmaceutical products as it has been considered suitable for their intended purpose, like quantitation of active ingredients (assay).
Since validated methods are applied routinely, some essential aspects must be observed during the technique development to avoid an excessive waste of financial resource. The mobile phase is an important factor to be considered during development of the HPLC method. Thus, solvents that have a low price and extend the column life are generally chosen. Also the choice of column should be such that it should be rugged, easily available; batch variation should be less and can sustain a longer life. Furthermore, the application of the method is relevant because it is fast and determines the range of linearity. The present work reports the development and validation of a method that can be applied for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in individual dosage form and in combination. Furthermore the method has stability indicating capability.
Experimental:
Chemicals & Reagents All solvents were of HPLC grade and all reagents were of analytical grade.
Triethylamine, ortho-phosphoric acid and hydrogen peroxide were obtained from SD Fine Chemicals (India). Acetonitrile, Hydrochloric acid, sodium hydroxide was obtained from Rankem (India). Water was purified with Milli-Q Plus, Millipore System (USA). All solvents and solutions were filtered through a membrane filter (Millipore Millex -HV filter units, 0.45 µm pore size; nylon) and degassed before use. All solutions were profiteered before injecting into HPLC system using Millipore milex hydrophilic PTFE unit filter of 0.45 µm pore size.
Instrumentation and Analytical Conditions
The HPLC method development and validation procedures was performed on Waters Alliance HPLC system (waters 2695 separation module), equipped with a photo diode array detector (Waters 2996 photo diode array detector). Data integration was performed using Empower-1 software. The analytical column was a normal phase 18e (250*4.6 mm, 5 µm particle size) (PUROSPHERE STAR RP). All analysis was carried out at a temperature of 40±2 °C under gradient conditions. The mobile phase consisted of a mixture of 0.2 % v/v Triethylamine buffer (pH 3.0, adjusted with diluted ortho-phosphoric acid): Acetonitrile. The flow rate was 1.0 mL/min, the volume of injection was 20 µL, all chromatograms were monitored in 200-400 nm range using Photo diode detector and the detection was made by extracting chromatogram at 215 nm in table 1. 
Method Development
The chromatographic conditions were adjusted in order to provide a good assay performance. Mobile phase selection was based on peak parameters (tailing) and run time.
Method Validation:
The method applied for the determination of Aliskiren, Ramipril, Valsartan and Hydrochlorothiazide in pharmaceuticals was validated according to the International Conference on Harmonisation guidelines for analytical procedures validation.
[29]
Linearity
The linearity was evaluated by linear regression analysis using the least square regression method. The calibration curve was obtained with fifteen concentrations of standard solution (20-120 % of nominal concentrations with 10 % increment) for the chromatographic method. Precision Six injections of the standard mixture were analyzed for the determination of system precision. Similarly six solutions of the individual standards were prepared and assayed for the determination of method precision. The possible interferences were analyzed by the peak purity, which was calculated using Empower-1 software. For degradation studies, samples were subjected to acidic, alkaline and oxidative degradation the resulting solutions were analyzed using proposed method. Robustness For the HPLC method, the robustness was determined by the analysis of the samples under a variety of conditions making small changes in the buffer pH (2.8 and 3.0), in the percentage of mobile phase component-±2.0 % (Buffer: ACN), in the flow rate (0.9 and 1.1 mL min -1 ), in the temperature conditions (35 ºC and 45 ºC) and by changing the wavelength of detection (210 and 220 nm).
Stability
The sample was analyzed for more than 27 hrs at room temperature i.e. at 25 ºC and found stable. 
Results and Discussion

